Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...

ICU Medical (NASDAQ:ICUI) and Otsuka Pharmaceutical Factory, a unit of Japan’s Otsuka, are launching a joint venture focused ...

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Pharmaceutical Factory America, a subsidiary of Otsuka Pharmaceutical Factory, has ...

ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim analysis the reduction of patients’ urine protein-to-creatine ratio ...

Alzheimer’s disease or dementia care is valued at $346.6 billion; contributing nearly 40% of the total family caregiving valuation.

An experimental medicine Otsuka Pharmaceutical acquired in a buyout six years ago has succeeded in a Phase 3 trial in a rare kidney disease, the company said Tuesday. The drug, called ...

Phase 3 VISIONARY study met its primary endpoint at prespecified interim analysis; sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour uPCR after ...

Otsuka Holdings Co., Ltd. is a leading healthcare company based in Japan, operating primarily in the pharmaceutical and nutraceutical sectors, and is recognized for its innovations in total ...